Effectiveness of Breast Cancer Recurrence Score Varies by Race


The 21-gene recurrence score can predict the benefits of adjuvant chemotherapy for certain breast cancer patients, but its effectiveness varies by race. A study published found that the score is a predictive biomarker for most early-stage estrogen receptor (ER)-positive, HER2-negative breast cancer cases. Asian or Pacific Islander patients did not benefit from the score, and it underestimated the benefits of adjuvant chemotherapy for non-Hispanic Black patients under 50. The research analyzed data on 73,363 patients with stage I-II, ER-positive, HER2-negative, axillary node-negative breast cancer, and found that adjuvant chemotherapy was associated with a significant reduction in the risk of breast cancer death for certain patient groups. Further studies are needed to confirm these findings.

Source link

error: Content is protected !!